India MCA Insolvency Liquidation Filings — March 30, 2026

Converted 12,90,000 warrants (originally from 48,00,000 at ₹200 each) into equity shares March 20-25, 2026, increasing Caprihans stake 3.57% pp to 59.56% from 55.99%, enhancing control in restructuring

Redeemed 31,50,000 0.1% Non-Cumulative Non-Participating Redeemable Preference Shares of Caprihans for ₹3.15 crore on March 23, 2026, deleveraging balance sheet

Completed voluntary liquidation of wholly-owned UK subsidiary Bilcare GCS Ltd on March 18, 2026, realizing GBP 195,781.83 proceeds (pending), streamlining non-core assets

Bilcare GCS contributed negligible 0.02% (₹11.88 lakh) to FY 2024-25 consolidated turnover, liquidation materially de-risks ops without revenue impact

Stake increase to 59.56% in Caprihans (post-conversion of 12.9L warrants) vs prior 55.99%, demonstrates conviction in subsidiary value amid restructuring

6th COC meeting on March 30, 2026, follows IRP (Oct 30, 2025) and RP (Jan 27, 2026) appointments, no resolution plan approved in 5 months

Consistent positive actions across two new filings (redemption + conversion + liquidation), relative outperformance vs Radhagobind's delays

Ongoing CIRP revision of resolution plans at 6th COC, signals weak creditor confidence and extended timeline

Original ₹96 crore warrant investment (48L at ₹200) partially converted, capital allocation favors equity consolidation over prefs

High materiality (9/10) negative sentiment vs Bilcare's 4-6/10 positive, relative underperformance in IBC progress

Ceased Bilcare GCS as subsidiary post-liquidation, reduces overseas exposure with minimal FY25 turnover impact

Bilcare's 100% clean-up of non-material sub vs Radhagobind's unresolved CIRP, superior restructuring execution

6th COC meeting March 30, 2026, 5 months since IRP appointment (Oct 30, 2025), no resolution plan finalized

Agenda includes revision of plans, indicating prior submissions inadequate, elevates liquidation risk under IBC

Materiality 9/10 with negative tone, contrasts Bilcare's positive filings

GBP 195,781.83 liquidation proceeds from Bilcare GCS not yet credited post March 18, 2026 completion

RP appointed Jan 27, 2026 via IA (I.B.C)/90(KB)2026, but no progress to resolution by March

Only 12,90,000 of 48,00,000 warrants converted, remaining exposure to Caprihans restructuring

6th COC chaired by Adv. Najeeb T P, repeated meetings signal stalled process

₹3.15 crore outflow for 31,50,000 prefs, minor cash impact but tied to Caprihans health

3.57% pp stake hike to 59.56% in Caprihans post-warrant conversion, potential for full control and value unlock

GBP 195k (~₹2 crore) from non-material sub (0.02% FY25 turnover), accretive to cash post-credit

Redemption of ₹3.15cr low-yield (0.1%) prefs improves Caprihans capital structure, upside for equity holders

6th COC on March 30, 2026, could approve revised plans, turnaround if resolution achieved

Two filings confirm positive actions (conversion + redemption + liquidation), undervalued if market overlooks IBC progress

Remaining ~35L warrants from original 48L investment at ₹200, cheap equity entry if further conversions

Ongoing CIRP since Oct 2025, opportunity for discounted bids if no resolution at 6th COC

Superior execution (stake up, sub liquidated) vs Radhagobind delays, relative alpha in pharma-packaging restructuring

Eliminated UK sub with negligible ₹11.88L FY25 contribution, focuses capex on core India ops

New RP (Adv. Najeeb T P) since Jan 2026, potential acceleration of CIRP at March 30 meeting

Bilcare's 3.57% pp stake increase to 59.56% via warrant conversion (12.9L shares) across 2/3 filings, trend towards control in IBC-linked entities for value capture [IMPLICATION: Bullish for parents in multi-entity distress]

Bilcare GCS (0.02% FY25 turnover, GBP 195k proceeds) voluntarily liquidated, common clean-up tactic with low revenue impact [IMPLICATION: De-risks balance sheets, minor cash positive]

Radhagobind's 6th COC (March 30, 2026) after 5 months, highlights delays post-IRP/RP appointments [IMPLICATION: Elevates liquidation risk, bearish for unresolved cases]

Bilcare redeemed ₹3.15cr 0.1% prefs in Caprihans, shifts capital from fixed income to equity control [IMPLICATION: Improves subsidiary leverage, supports turnaround theses]

Positive (Bilcare 4-6/10) vs negative high-materiality (Radhagobind 9/10), 2/3 positive on execution vs 1/3 delays [IMPLICATION: Selective opportunities in proactive restructurings]

Bilcare's GBP 195k post-March 18 completion, typical lag in overseas voluntary processes [IMPLICATION: Near-term cash catalysts to monitor]

Monitor outcomes on CIRP progress, resolution plan revisions; March 30, 2026 at 4 PM (Kannur/Virtual)

Track crediting of GBP 195,781.83 from Bilcare GCS UK liquidation; post March 18, 2026

Watch for further conversions of ~35L warrants in Caprihans (orig 48L at ₹200); post March 25, 2026

Follow Adv. Najeeb T P actions/emails (najetpip@gmail.com) post-COC for resolution timeline

Any additional allotments or prefs redemptions building on 59.56% stake; Q1 CY2026

Next orders post-6th COC, given prior CP (IB)/71/KB/2025 & IA/90(KB)2026

Confirm Bilcare GCS fully ceased, impact on FY26 consolidateds (was 0.02% FY25)

Monitor radhagobindcirp2025@gmail.com & +91-9846603236 for plan approvals